{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36758089",
  "DateCompleted": {
    "Year": "2023",
    "Month": "03",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2023",
        "Month": "02",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1126/science.adh0582"
    ],
    "Journal": {
      "ISSN": "1095-9203",
      "JournalIssue": {
        "Volume": "379",
        "Issue": "6632",
        "PubDate": {
          "Year": "2023",
          "Month": "Feb",
          "Day": "10"
        }
      },
      "Title": "Science (New York, N.Y.)",
      "ISOAbbreviation": "Science"
    },
    "ArticleTitle": "Could a popular antiviral supercharge the pandemic?",
    "Pagination": {
      "StartPage": "526",
      "MedlinePgn": "526"
    },
    "Abstract": {
      "AbstractText": [
        "Molnupiravir appears to be speeding SARS-CoV-2 evolution."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Service",
        "ForeName": "Robert F",
        "Initials": "RF"
      }
    ],
    "PublicationTypeList": [
      "News"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Science",
    "NlmUniqueID": "0404511",
    "ISSNLinking": "0036-8075"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "YA84KI1VEW",
      "NameOfSubstance": "molnupiravir"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Hydroxylamines"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "transmission",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Hydroxylamines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Genome, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Assessment"
    }
  ]
}